Meta tags:

Headings (most frequently used words):

of, board, in, aureus, chief, officer, precision, us, atopic, dermatitis, the, cycle, team, potential, matt, regan, dr, head, member, eliminationof, disease, driving, pathogens, about, why, this, matters, by, selectively, eliminating, we, aim, to, break, and, restore, biological, balance, leadership, directors, latest, news, contact, one, solution, broad, selective, powerful, resistance, resilient, transformative, overgrowth, barrier, disruption, flares, matthew, dunne, martin, vlasaty, markus, huemer, fabienne, arn, bob, de, rooij, hana, pituerova, vincent, kobesen, patrick, vink, partnership, with, northway, biotech, cdmo, introducing, mendob, biologic, targeting, staphylococcus, new, data, published, blood, supports, engineered, endolysins, ctcl, executive, director, development, science, financial, protein, engineering, principal, scientist, preclinical, lab, manager, chair, investor, ceo,

Text of the page (most frequently used words):
and (36), micreos (22), the (22), with (16), our (10), disease (8), that (7), engineered (7), #precision (7), team (7), view (7), profile (7), development (7), pathogens (7), for (6), from (6), aureus (6), over (6), experience (6), zurich (6), skin (6), contact (5), matt (5), designed (5), board (5), years (5), protein (5), officer (5), atopic (5), dermatitis (5), selectively (5), regan (4), university (4), new (4), staphylococcus (4), potential (4), endolysins (4), lead (4), biologics (4), program (4), joined (4), 2021 (4), has (4), research (4), engineering (4), leadership (4), chief (4), inflammation (4), are (4), driving (4), pharmaceuticals (3), ceo (3), read (3), more (3), endolysin (3), news (3), member (3), hana (3), laboratory (3), since (3), scientist (3), fabienne (3), brings (3), antimicrobial (3), eth (3), science (3), serves (3), markus (3), diseases (3), based (3), including (3), martin (3), finance (3), matthew (3), across (3), biological (3), balance (3), cycle (3), this (3), flares (3), imbalance (3), barrier (3), microbiome (3), associated (3), while (3), healthy (3), harmful (3), about (3), 2026 (2), scientific (2), published (2), blood (2), 2024 (2), update (2), publication (2), mendob (2), biologic (2), targeting (2), cdmo (2), northway (2), biotech (2), therapeutic (2), operations (2), wädenswil (2), august (2), technician (2), manager (2), analytical (2), clinical (2), bob (2), experienced (2), therapeutics (2), head (2), senior (2), internationally (2), recognized (2), expert (2), infectious (2), microbiology (2), director (2), leads (2), 2022 (2), company (2), deep (2), expertise (2), patient (2), care (2), platform (2), technology (2), one (2), broad (2), selective (2), elimination (2), future (2), restore (2), chronic (2), recurrent (2), microbial (2), severity (2), overgrowth (2), eliminate (2), preserving (2), protects (2), conditions (2), starting (2), proprietary (2), believe (2), what (2), resistance (2), home (2), privacy, cookies, follow, linkedin, neuhofstrasse, 6340, baar, switzerland, com, enquiries, investment, discussions, strategic, partnerships, general, information, please, study, copenhagen, provides, evidence, january, data, supports, ctcl, pleased, introduce, february, introducing, partners, its, manufacturing, march, 2025, partnership, press, release, latest, patrick, vink, chair, investor, vincent, kobesen, directors, making, sure, run, smoothly, efficiently, possible, allow, achieving, best, results, within, ever, she, worked, both, providing, support, scientists, later, lab, pituerova, developed, pre, models, investigate, mode, action, optimal, dosing, strategy, biomedical, specialised, validating, safety, efficacy, novel, preclinical, rooij, method, trained, chemical, holds, master, msc, chemistry, applied, sciences, september, principal, arn, 800, citations, phd, immunology, hospital, biosafety, huemer, meet, roche, genentech, bluebird, bio, arena, track, record, building, scaling, business, corporate, governance, role, held, december, financial, vlasaty, genetic, april, dunne, pharmaceutical, seven, countries, spanning, healthcare, value, chain, global, companies, abbott, abbvie, novo, nordisk, led, october, executive, combines, drug, shared, commitment, transforming, leaders, driven, purpose, multiple, indications, beyond, core, focus, solution, benefits, hypothesized, restoration, evaluated, studies, eliminating, aim, break, vicious, intense, itch, toxin, production, further, weaken, exacerbate, symptoms, disruption, colonization, disrupts, increased, why, matters, conventional, therapies, fail, address, underlying, compromised, creates, enable, pathogen, closely, profound, center, swiss, biotechnology, pioneering, class, essential, human, health, through, long, standing, collaboration, zürich, advancing, dermatology, oncology, other, areas, where, drive, amplify, impair, patients, healing, recovery, lies, medicines, drives, protecting, keeps, reimagining, how, treated, unlocking, treatment, paradigms, high, unmet, medical, need, transformative, overcome, mechanisms, resilient, potent, activity, even, against, resistant, strains, biofilms, powerful, target, specific, bacterial, explore, make, vision, reality, most, prevalent, inflammatory, should, eliminated, biology,

Text of the page (random words):
micreos micreos precision biologics home about us lead program our team news contact micreos home about us lead program our team news contact 2026 micreos precision elimination of disease driving pathogens at micreos we believe that disease driving pathogens should be selectively eliminated while preserving the healthy biology that protects us our proprietary engineered endolysins are precision biologics designed to make that vision a reality starting with one of the most prevalent chronic inflammatory skin conditions atopic dermatitis explore our lead program contact us selective designed to target specific harmful bacterial pathogens powerful potent activity even against resistant strains and biofilms resistance resilient engineered to overcome pathogens resistance mechanisms transformative unlocking new treatment paradigms for diseases with high unmet medical need about us reimagining how disease driving pathogens are treated micreos is a swiss based biotechnology company pioneering a new class of precision biologics designed to selectively eliminate disease driving pathogens and restore the biological balance essential to human health through a long standing collaboration with eth zürich and with deep expertise in microbiology protein engineering and therapeutics development we are advancing our proprietary engineered endolysin platform with broad potential across dermatology oncology infectious diseases and other therapeutic areas where harmful pathogens drive disease amplify inflammation or impair patients healing and recovery we believe the future of care lies in precision medicines targeting what drives disease while protecting what keeps us healthy micreos r d technology center wädenswil zurich starting with atopic dermatitis atopic dermatitis ad is associated with a profound imbalance in the skin microbiome a compromised skin barrier creates conditions that enable the overgrowth of staphylococcus aureus a harmful pathogen closely associated with inflammation disease severity and recurrent flares conventional therapies fail to selectively address this underlying microbial imbalance our engineered endolysins are designed to selectively eliminate staphylococcus aureus while preserving the healthy microbiome that protects the skin why this matters in atopic dermatitis s aureus overgrowth over colonization disrupts the skin microbiome and is associated with increased inflammation and disease severity barrier disruption microbial imbalance and toxin production further weaken the skin barrier and exacerbate symptoms cycle of flares this vicious cycle leads to chronic inflammation intense itch and recurrent flares by selectively eliminating s aureus we aim to break the cycle and restore biological balance patient benefits hypothesized from selective elimination of s aureus and restoration of biological balance to be evaluated in future clinical studies one solution broad potential a platform technology with potential across multiple indications beyond our core focus in atopic dermatitis leadership team experienced leaders driven by purpose our team combines deep scientific expertise drug development experience and a shared commitment to transforming patient care matt regan chief executive officer director view profile matt is ceo and board member of micreos and has led the company since october 2021 matt brings over 30 years of pharmaceutical leadership experience across seven countries spanning the healthcare value chain with global companies including abbott abbvie and novo nordisk matthew dunne chief development science officer view profile matthew joined micreos in april 2022 and serves as chief development science officer matthew is an internationally recognized expert with over 15 years of experience in research genetic engineering and protein based antimicrobial development including senior research leadership at eth zurich martin vlasaty chief financial officer view profile martin leads finance at micreos a role he has held since december 2022 martin brings over 13 years of finance leadership experience from roche genentech bluebird bio and arena pharmaceuticals with a track record of building and scaling finance business operations and corporate governance meet the micreos r d team r d team dr markus huemer head of protein engineering view profile markus joined micreos in august 2021 and serves as director of protein engineering and biosafety officer markus is an internationally recognized expert with over 10 years of experience in research 1 800 citations infectious diseases and protein based antimicrobial development including a phd in microbiology and immunology from the university of zurich university hospital zurich fabienne arn principal scientist view profile fabienne joined micreos in september 2021 and serves as senior scientist fabienne brings over 8 years of experience in antimicrobial research and analytical method development is a trained chemical technician from eth zurich and holds a master of science msc in chemistry from the zurich university of applied sciences dr bob de rooij head of preclinical view profile bob is an experienced biomedical scientist specialised in validating safety and efficacy for novel therapeutics at micreos he has developed analytical and pre clinical models to investigate the mode of action and optimal dosing strategy for endolysins hana pituerova lab manager view profile hana joined micreos in august 2021 ever since she has worked both as a laboratory technician providing support to micreos scientists and later as a laboratory manager hana is making sure that the laboratory operations in wädenswil run as smoothly and efficiently as possible to allow for achieving the best results within the r d team board of directors vincent kobesen board chair investor patrick vink board member matt regan ceo board member latest news press release partnership with northway biotech cdmo march 4 2025 micreos pharmaceuticals partners with biologics cdmo northway biotech for its engineered endolysin therapeutic manufacturing program read more publication update introducing mendob a precision biologic targeting staphylococcus aureus february 6 2024 micreos is pleased to introduce mendob our lead engineered endolysin and a precision biologic designed read more publication update new data published in blood supports the potential of engineered endolysins in ctcl january 11 2024 a study from the university of copenhagen published in blood provides new evidence that staphylococcus read more contact us for scientific enquiries investment discussions strategic partnerships or general information please contact our ceo matt regan m regan micreos com micreos pharmaceuticals ag neuhofstrasse 12 6340 baar switzerland follow micreos on linkedin 2026 micreos cookies privacy